Cost-effectiveness of phosphate binders among patients with chronic kidney disease not yet on dialysis: a long way to go by unknown
COMMENTARY Open Access
Cost-effectiveness of phosphate binders
among patients with chronic kidney




Hyperphosphatemia management is integral to the management of patients with chronic kidney disease. This
mineral abnormality is associated with greater costs, but so is its management, especially with the use novel
phosphate binders. The economic evaluation of these pharmaceutical agents is increasingly needed to provide
evidence for value of money spent and inform resource allocation. Recently, Nguyen et al. explored the economical
attractiveness of Sevelamer relative to Calcium Carbonate among patients with chronic kidney disease not yet on
dialysis and concluded that the former was cost-effective. The current commentary discusses the results of this
analysis and sheds light on the methodological challenges of economic evaluations in this field.
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Background
Hyperphosphatemia is consistently and independently
associated with increased morbidity and mortality
among end stage renal disease patients [1–3], and results
in financial burdens for health systems [4]. Although this
issue was explored to a lesser extent among patients
with chronic kidney disease (CKD), results from large
studies suggest an independent association between ele-
vated serum phosphorus levels and increased patient
mortality risk [5, 6]. The association between hyperpho-
sphatemia and progression to dialysis initiation has also
been suggested. However, this association was inconsist-
ent across studies [7] and was rendered not statistically
significant when potential confounders were accounted
for in the analysis [6]. Despite this, serum phosphorus
management in CKD patients has gained increasing im-
portance in contemporary nephrology practice, and tight
targets for serum phosphorus levels were set for these
patients, although, up-till-now, we still lack conclusive
evidence, ie prospective interventional studies, to
demonstrate that reduction in serum phosphate im-
proves CKD patient outcomes.
Concerns about the high cost of hyperphosphatemia’s
consequences are offset by concerns about hyperpho-
sphatemia’s high treatment cost [8], especially with the
novel pharmaceuticals, ie non-calcium-based phosphate
binders. Within this scope, economic evaluations -stud-
ies providing evidence for value of money spent- are now
being increasingly used by public health decision makers
to guide the allocation of scarce resources [9].
Main text
The cost-effectiveness of phosphate binders was first ad-
dressed among hemodialysis patients, where due to
many factors, the management of serum phosphorus is a
continuous challenge. Since 2005, multiple full economic
evaluations were published in this regards. In 2016, the
comparative cost-effectiveness of these agents was sys-
tematically explored by Rizk et al. [10], where in view of
the suboptimal quality and inconsistent results of in-
cluded studies, robust conclusions could not be gener-
ated. The authors of the review suggested that calcium-
based binders- especially Calcium Acetate was the most
economically attractive therapy, in first-line and
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sequential use, in prevalent patients, and that Lan-
thanum Carbonate might provide good value for money,
as second-line therapy, in incident patients. In that re-
view, the incremental cost-utility ratio of Sevelamer rela-
tive to Calcium Carbonate ranged between US$36,803
and US$157,760 per quality adjusted life year (QALY)
gained for first-line use among prevalent patients. Rela-
tive to the same comparator, Sevelamer was borderline
cost-effective among incident patients (US$47,153).
So far, the comparative cost-utility of phosphate
binders among renal patients not yet on dialysis was
only explored in two studies. The first by Vegter et al.
[11] concluded that second-line Lanthanum Carbonate
dominated -less costly and more effective- calcium-based
binders. Cost savings were mainly attributed to the de-
layed CKD progression and dialysis initiation. The sec-
ond study by Thompson et al. [12] concluded that first-
line Sevelamer was cost-effective compared with Cal-
cium Carbonate (incremental cost of £23,878 per QALY
gained (US$36,475)). However, in this study, the results
were most sensitive to alternative assumptions regarding
the impact of Sevelamer on dialysis initiation. Both stud-
ies [11, 12] adopted the perspective of the National
Health Service in the United Kingdom and used a life-
long Markov model. Accordingly, one would suggest
that the cost-effectiveness of non-calcium based binders
is mainly driven by their perceived effect on delaying the
treatment by dialysis.
This issue of BMC Nephrology includes the third full
economic evaluation of phosphate binders among pa-
tients with CKD not yet on dialysis. The article by
Nguyen et al. [13] assessed the life-time incremental
cost-utility of first-line Sevelamer relative to Calcium
Carbonate from the perspective of a third party payer in
Singapore, using a Markov model. This study was
funded by Sanofi-Aventis (Singapore). The authors con-
cluded that Sevelamer produces an incremental cost-
utility ratio of S$51,756 (US$38,500) per QALY gained
relative to Calcium Carbonate.
In contrast to the above-mentioned two studies, where
country-specific clinical evidence was readily available
for the analysis, Nguyen et al. [13] employed a multitude
of clinical effectiveness sources to construct their model,
some of which were extracted from divergent patient
population groups. In order to circumvent limitations of
available Singapore-specific data, especially survival out-
comes (mortality risks among Singaporean CKD and
dialysis patients), the authors used age-specific mortality
risks from Singapore life-tables, mortality hazard ratios
for CKD patients based on a large Taiwanese cohort
study and adjusted age-specific mortality risks from the
United States Renal Data System. However, other key
parameters used in the model, such as the probabilities
for transitioning to dialysis or the needed dose of
Sevelamer to reach a certain level of effectiveness were
directly extrapolated from divergent patient groups [14]
to the study’s population. This issue must be revisited
and further research in this regards must be conducted
in order to inform public health decision making, espe-
cially that the sensitivity analyses showed that Sevelamer
became less economically attractive with higher dialysis
costs and at higher Sevelamer doses. Finding readily
available country-specific data for model inputs or infor-
mation to adjust data from other countries is a consist-
ent challenge across model-based economic evaluation
studies, especially those conducted in low and middle in-
come countries. This was repeatedly faced by authors
from these countries in the field of phosphate-binder re-
lated research among renal patients [10].
Similarly, although Nguyen et al. [13] presented thor-
ough details of the data used for constructing the model,
caution must be taken when directly extrapolating their
results to be used in other countries. In fact, the incre-
mental cost-utility ratio of Sevelamer versus Calcium
Carbonate was most sensitive to changes in the cost of
the former. This agent was shown to be no longer cost-
effective at the price of S$1.69/g (US$1.26/g). Given the
changes in the costs of therapeutic agents across coun-
tries [15, 16], the direct transferability of these results is
questioned [16]. This issue was also pinpointed in other
areas of economic evaluations of health care interven-
tions [17]. In fact, strong evidence points out the chal-
lenging and complex task of the transferability of
economic evaluation data across countries, and that
transferability requires a minimum of country-specific
substitution of practice pattern data, in addition to unit
cost data [16].
On the other hand, Grima et al. [18] presented the
case for excluding dialysis costs in economic evaluations
of interventions that increase survival, such as phosphate
binders. The authors argued that due to the high cost of
dialysis, the inclusion of its costs in the analysis of any
life-extending intervention eliminates the possibility of
obtaining a favorable cost-effectiveness ratio, regardless
of the clinical benefits of the intervention. According to
the authors, this might deny renal patients access to in-
terventions that are initially cost-effective. Assessing the
impact of excluding future dialysis costs in the sensitivity
analyses would have presented a more realistic look at
the cost-effectiveness of Sevelamer. Moreover, non-
calcium based phosphate binders seem to be more eco-
nomically attractive when used as a second line therapy
among dialysis and non-dialysis patients [10, 11]. In
depth exploration of this issue would have been interest-
ing in order to inform decision making, especially in
countries with limited health resources.
This study was funded by a pharmaceutical company.
Previous systematic reviews of the literature [19, 20]
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found that pharmaco-economic studies sponsored by
the industry were more likely to favor the sponsor’s
product. This was also the case of publications on phos-
phate binders for hyperphosphatemia management [10].
Sponsor bias (specifically in trial-based economic evalua-
tions) was thoroughly discussed by Evers et al. [21] and
solutions to overcome it, beyond disclosure of the finan-
cial conflict of interest and a rigorous peer-review
process, included maintenance of good methodological
standards. This highlights the pressing need for stringent
guidelines governing the conduct and publication of eco-
nomic evaluations.
Finally, in contrast to the case of hemodialysis pa-
tients, where various evidence-based practice guidelines
agree on actively managing hyperphosphatemia, this
issue is less clear among patients not receiving dialysis.
While the Kidney Disease: Improving Global Outcomes
(KDIGO) guidelines [22] recommend maintaining serum
phosphate levels “within the normal range” starting stage
3 or 4 of the disease, the United Kingdom National In-
stitute for Health and Clinical Excellence (NICE) guide-
lines [23] suggest that serum phosphate should be
monitored routinely only in stages 4, 5, and 5d. Never-
theless, in all of the above-mentioned cases, the guide-
lines were not based on definitive evidence on the
beneficial effect of lowering phosphate levels in early or
late CKD.
Conclusion
In conclusion, evaluating the outcomes of the imple-
mentation of renal guidelines pertaining to serum phos-
phorus management in terms of reduced morbidity,
mortality and delayed dialysis initiation is becoming im-
perative. This would pave the way for a more rationale
evaluation of the cost-effectiveness of interventions in
this regards. Until then, employing borderline cost-
effective phosphate binders to achieve tight serum phos-
phorus levels, where supportive conclusive evidence sur-
rounding the clinical or financial benefits is lacking, is to
be discussed in the light of the country-specific health
priorities and budgetary limitations.
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